Zulitor Tablets 4mg

Booth No: M426

Characteristic

Zulitor (pitavastatin 4mg) demonstrates strong efficacy and safety across both pre-marketing trials and post-marketing real-world studies, making it a highly suitable option for patients at elevated cardiovascular risk. According to Asian clinical studies have shown that high-dose pitavastatin (4mg) reduces cardiovascular event risk by 19% and lowers LDL-C levels by up to 47%.

Importantly, Zulitor has minimal impact on glycemic control in both diabetic and non-diabetic patients and is metabolized via a non-CYP450 pathway, reducing the risk of drug-drug interactions. Post-marketing safety data from Taiwan’s National Health Insurance Research Database further confirm the favorable safety profile of pitavastatin, showing a lower incidence of hepatotoxicity, rhabdomyolysis, and new-onset diabetes compared to other statins. These findings enhance the clinical confidence in Zulitor as an optimal lipid-lowering therapy, particularly for patients with complex comorbidities.

Other Products

Products you may be interested in

Highest Rated Products

Back

Menu

Zulitor Tablets 4mg

Characteristic

Other Products

Products you may be interested in

Highest Rated Products